Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts TSHA Hot Sheet
Join SI Premium – FREE
Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.98 million versus the consensus estimate of $1.82 million.
For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel on FedEx Freight (FDXF): 'Enters Its Post-Breakup Era - Time to Hit the Gym and Focus on Itself'
- Amazon Taps $80 Billion Supplier Loan Facility To Help Fund AI - Bloomberg
- Micron Technology shares fall on China chip concerns, AI sector selloff
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
